The CD3-Zeta Chimeric Antigen Receptor Overcomes TCR Hypo-Responsiveness of Human Terminal Late-Stage T Cells (original) (raw)

Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

Mehdi Lakhal

Molecular Therapy, 2009

View PDFchevron_right

Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity

Misty Jenkins

Proceedings of the National Academy of Sciences

View PDFchevron_right

A Novel Peptide-MHC Targeted Chimeric Antigen Receptor T Cell Forms a T Cell-like Immune Synapse

Misty Jenkins

Biomedicines

View PDFchevron_right

CD3ζ-based chimeric antigen receptors mediate T cell activation via cis - and trans -signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy

Kelly l. Miners

Clinical & Experimental Immunology, 2014

View PDFchevron_right

Adequate synapse formation between leukemic B cells and effector T cells following stimulation with artificial TCR ligands

Eric Eldering

Leukemia & Lymphoma, 2008

View PDFchevron_right

An entirely humanized CD3 ζ-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells

Prof.dr.REINDER LH BOLHUIS

International Journal of Cancer, 2000

View PDFchevron_right

Gated chimeric antigen receptor T-cells: the next logical step in reducing toxicity?

John Maher

Translational Cancer Research, 2016

View PDFchevron_right

T Cell Receptor zeta Allows Stable Expression of Receptors Containing the CD3gamma Leucine-based Receptor-sorting Motif

Jes Dietrich

Journal of Biological Chemistry, 1998

View PDFchevron_right

T cells expressing chimeric antigen receptor promote immune tolerance

Jeanette Baker

JCI insight, 2017

View PDFchevron_right

Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies

Kevin Chen

Oncotarget, 2016

View PDFchevron_right

-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

Pakin Boonrat

View PDFchevron_right

The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy

Dongfang Liu

Cell Communication and Signaling

View PDFchevron_right

Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments

Manel Juan

Frontiers in Immunology

View PDFchevron_right

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility

Dhwani Radhakrishnan

Journal of Translational Medicine

View PDFchevron_right

Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo

Raphael Sandaltzopoulos

Cancer immunology research, 2013

View PDFchevron_right

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

John Maher

Nature Biotechnology, 2002

View PDFchevron_right

Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells

Markus Chmielewski

Frontiers in immunology, 2013

View PDFchevron_right

Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives

Tara Gregory

Current Research in Translational Medicine, 2017

View PDFchevron_right

Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies

Jennifer Stone

View PDFchevron_right

Receptor Protein-HLA-DR2-{zeta} Chimeric Myelin Basic Lymphocytes Using a Humanized against Myelin-Specific T Redirecting Therapeutic T Cells

Phuong Nguyen

View PDFchevron_right

Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer

Marc Schmitz

Journal of Biomedicine and Biotechnology, 2010

View PDFchevron_right

Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells

Qianru Wei

Cellular & Molecular Immunology

View PDFchevron_right

Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells

Dongfang Liu

Molecular therapy : the journal of the American Society of Gene Therapy, 2018

View PDFchevron_right

Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions

Alaa A . Alnefaie

Frontiers in Bioengineering and Biotechnology, 2022

View PDFchevron_right

Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs)

Laura Patrussi

International Journal of Molecular Sciences

View PDFchevron_right

TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity

Marc Schmitz

OncoImmunology, 2013

View PDFchevron_right

The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity

Jonathan Bramson, Craig Aarts, Lisa Newhook

View PDFchevron_right

Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines

Udo Hartwig

Blood, 2007

View PDFchevron_right

Arming Cytokine-induced Killer Cells With Chimeric Antigen Receptors: CD28 Outperforms Combined CD28–OX40 “Super-stimulation”

Gunter Rappl

Molecular Therapy, 2013

View PDFchevron_right

Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells

Nabil Hagag

Leukemia, 2015

View PDFchevron_right

Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells

Usanarat Anurathapan

Molecular Therapy, 2014

View PDFchevron_right

The CD3 Conformational Change in the γδ T Cell Receptor Is Not Triggered by Antigens but Can Be Enforced to Enhance Tumor Killing

Balbino Alarcón

Cell Reports, 2014

View PDFchevron_right

through use of a novel T cell antigen receptor. A universal strategy for adoptive immunotherapy of cancer Updated Version E-mail alerts A universal strategy for adoptive immunotherapy of cancer through use of a novel T cell antigen receptor

Mathilde Poussin

2020

View PDFchevron_right